Traws Pharma, Inc.
Close on Oct 19, 2026
- Market cap
- $5.81M
- P/E (TTM)
- 0.4
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | After market close | – | $-0.16 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 15, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-0.34 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | $2.70M | $-0.11 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | $57.00K | $2.09 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | $57.00K | $-8.81 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 15, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 16, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 10, 2023 | After market close | – | – | – |
Press releases
Announcements Traws Pharma filed with the SEC
Reports Q2 2026 Financial Results and Provides Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Updated Guidance on Influenza Prophylaxis Program
Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Regulatory Update on Influenza Program
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Highlights and Reports Q1 2026 Financial Result s
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Reports Full Year 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Up to $60 Million Private Placement Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID ® -Eligible and Ineligible COVID-19 Patients and Provides
Other events · EX-99.1 to Form 8-K
Traws Pharma Completes Enrollment of Ratutrelvir
Other events · EX-99.1 to Form 8-K
Traws Pharma Files Tivoxavir Marboxil Investigational
Other events · EX-99.1 to Form 8-K
Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19
Other events · EX-99.1 to Form 8-K
Reports Third Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Phase 2a COVID19 Study Design 19 Outcome Measures Include • Symptom relief • Hospitalization • Death • PK • Virus burden • Frequency of clinical rebound • Timing of clinical rebound
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Other events · EX-99.1 to Form 8-K
Adds John Leaman, MD as Independent Director and Formalizes Appointments of Two Key Executives
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase 2a COVID19 Study Design 19 Outcome Measures Include • Symptom relief • Hospitalization • Death • PK • Virus burden • Frequency of clinical rebound • Timing of clinical rebound
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Pharma Reports Second Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Phase 2a COVID19 Study Design 19 Outcome Measures Include • Symptom relief • Hospitalization • Death • PK • Virus burden • Frequency of clinical rebound • Timing of clinical rebound
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Bird Flu Tivoxavir marboxil (TXM, TRX100) A single - dose investigational, CAP - dependent endonuclease inhibitor for treatment or prevention of H5N1 bird flu 9
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Traws Pharma Advances Antiviral Pipeline with
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Traws Pharma - Rigosertib June 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Traws Pharma Narazaciclib June 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Traws Pharma Announces Publication of Compelling
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Bird Flu Tivoxavir marboxil (TXM, TRX100) A single - dose investigational, CAP - dependent endonuclease inhibitor for treatment or prevention of H5N1 bird flu 9
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Traws Pharma Announces Receipt of FDA Guidance
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Bird Flu Tivoxavir marboxil (TXM, TRX100) A single - dose investigational, CAP - dependent endonuclease inhibitor for treatment or prevention of H5N1 bird flu 9
Regulation FD disclosure · EX-99.1 to Form 8-K
Traws Pharma Reports First Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Traws Pharma Reports Full Year 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Event March 31, 2025 Targeting Critical Threats to Human Health
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Traws Pharma’s COVID-19 Candidate, Ratutrelvir,
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Traws Pharma Antiviral Bird Flu Program, Tivoxavir
Other events · EX-99.1 to Form 8-K
Traws Pharma’s Bird Flu Drug Candidate,
Other events · EX-99.1 to Form 8-K
Tivoxavir marboxil, an Influenza Inhibitor Targeting
Other events · EX-99.2 to Form 8-K
Traws Pharma Reports Positive Results from An
Other events · EX-99.1 to Form 8-K
Traws Pharma Regains Compliance with NASDAQ
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Traws Pharma Announces Completion of Phase I
Other events · EX-99.1 to Form 8-K
Pharma, Inc. Announces Financing up to $72.6 Million from Leading
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K